Showing posts with label Antitrust. Show all posts
Showing posts with label Antitrust. Show all posts

Friday, March 31, 2023

Antitrust - An HSR Filing Cannot Be Made on a Hypothetical Deal


Competition Law

 

Antitrust

 

Hart-Scott-Rodino Compliance

 

Premerger Notification

 

An HSR Filing Cannot Be Made on a Hypothetical Deal

 

 

 

FTC

Republication

Spring Meeting updates

March 31, 2023

 

https://www.ftc.gov/enforcement/competition-matters/2023/03/spring-meeting-updates?utm_source=govdelivery

 

 

 

An HSR filing cannot be made on a hypothetical deal. The PNO (Premerger Notification Office) receives thousands of filings every year and sometimes it is important to remind the antitrust bar of some very basic principles of HSR compliance. For instance, the HSR Rules do not permit filing on hypothetical deals. This has been true from the beginning of the premerger program. Here is what the Commission said back in 1978: “because of the time and resource constraints on agency staff, the Agencies should not expend resources to review transactions so lacking in specifics that they could be considered merely hypothetical.” (43 Fed. Reg. 33,450 at 510-511). That means that for transactions in which a definitive agreement has not yet been executed, there must be an agreement in principle or letter of intent executed by the parties. A mere indication of interest or a document that is no more than an agreement to file HSR and wait to see what the Agencies do is not sufficient. The certification requirement is meant to ensure that the parties each have a good faith intent to consummate the transaction they describe

Monday, April 11, 2022

California Court of Appeal, The People v. Johnson & Johnson, Docket No. D077945

Antitrust

 

Trade Regulation

 

Unfair Competition

 

Misleading Statements

 

False Advertising

 

Design Defect and Failure-to-Warn Theories of Liability

 

The FDA Did Not Create a Safe Harbor

 

Statute of Limitations

 

Tolling Agreement

 

Consumer Law

 

Drugs & Biotech

 

Health Law

 

California Law

 

 

 

Johnson & Johnson, Ethicon, Inc., and Ethicon US, LLC (collectively, Ethicon) appeal an adverse judgment following a bench trial. The trial court levied nearly $344 million in civil penalties against Ethicon for willfully circulating misleading medical device instructions and marketing communications that misstated, minimized, and/or omitted the health risks of Ethicon’s surgically-implantable transvaginal pelvic mesh products. The court found Ethicon committed 153,351 violations of the Unfair Competition Law (UCL) (Bus. & Prof. Code, § 17200 et seq.) and 121,844 violations of the False Advertising Law (FAL) (§ 17500 et seq.), and it imposed a $1,250 civil penalty for each violation.

(Further undesignated statutory references are to the Business and Professions Code.)

 

(…) In 2008, the U.S. Food and Drug Administration (FDA) issued a public health notification alerting health care providers about complications from pelvic mesh implants used to treat SUI and POP.

 

(…) In 2012, the FDA ordered Ethicon to conduct post-market surveillance studies for one of its SUI devices (TVT-Secur) and three of its POP devices (Prolift, Prolift-M, and Prosima). Instead of conducting these post-market surveillance studies, Ethicon stopped selling the products commercially. Ethicon also changed the indication for its fourth POP device (Gynemesh PS) from a transvaginal indication to an abdominal-only indication. Ethicon continued selling its other SUI devices (TVT, TVT-Obturator, TVT-Abbrevo, and TVT-Exact) up to and throughout the present lawsuit.

 

Ethicon’s competitors continued to sell pelvic mesh products for transvaginal repair of POP, even after Ethicon stopped selling most of its POP devices. However, in April 2019, the FDA concluded there was not a reasonable assurance of safety and effectiveness for any commercially- available pelvic mesh products intended for transvaginal repair of POP. Therefore, the FDA ordered all remaining manufacturers of surgical mesh intended for transvaginal repair of POP to stop selling and distributing such products.

 

Ethicon’s Communications About Its Pelvic Mesh Products 

During the relevant timeframe, Ethicon disseminated three categories of communications giving rise to the violations at issue here: (1) Instructions for Use (IFUs); (2) marketing communications directed to California doctors; and (3) marketing communications directed to California patients.

 

(…) In 2016, the Attorney General filed an enforcement action against Ethicon on behalf of the People of the State of California. The operative complaint alleged Ethicon violated the UCL and FAL by disseminating deceptive advertisements relating to its pelvic mesh products.

 

(…) The UCL has a four-year statute of limitations (§ 17208) and the FAL has a three-year statute of limitations (Code Civ. Proc., § 338, subd. (h)). However, the parties executed a tolling agreement, effective October 17, 2012. Thus, the earliest date Ethicon could be held liable for UCL violations was October 17, 2008, and the earliest date it could be held liable for FAL violations was October 17, 2009. 

 

Governing Laws

 

 

Unfair Competition Law

 

The Unfair Competition Law, or UCL, forbids unfair competition, which is defined as “any unlawful, unfair or fraudulent business act or practice and unfair, deceptive, untrue or misleading advertising and any act prohibited by” the False Advertising Law.  (§ 17200.)  The UCL’s “ ‘purpose is to protect both consumers and competitors by promoting fair competition in commercial markets for goods and services.’ ”  (Abbott Laboratories v. Superior Court (2020) 9 Cal.5th 642, 651 (Abbott Labs).)“ ‘In service of that purpose, the Legislature framed the UCL’s substantive provisions in “ ‘broad, sweeping language’ ” ’ [citation] to reach ‘anything that can properly be called a business practice and that at the same time is forbidden by law’ [citation].  ‘By proscribing “any unlawful” business practice, “section 17200 ‘borrows’ violations of other laws and treats them as unlawful practices” that the unfair competition law makes independently actionable.’ ”  (Abbott Labs, supra, 9 Cal.5th at pp. 651–652.)  “However, the law does more than just borrow.  The statutory language referring to ‘any unlawful, unfair or fraudulent’ practice makes clear that a practice may be deemed unfair even if not specifically proscribed by some other law.  ‘Because ... section 17200 is written in the disjunctive, it establishes three varieties of unfair competition—acts or practices which are unlawful, or unfair, or fraudulent.’ ”  (Cel-Tech Communications, Inc. v. Los Angeles Cellular Telephone Co. (1999) 20 Cal.4th 163, 180 (Cel-Tech).)

 

 

False Advertising Law

 

The False Advertising Law, or FAL, “broadly prohibits false or misleading advertising, declaring that it is unlawful for any person or business to make or distribute any statement to induce the public to enter into a transaction ‘which is untrue or misleading, and which is known, or which by the exercise of reasonable care should be known, to be untrue or misleading.’ ”  (Nationwide Biweekly Administration, Inc. v. Superior Court (2020) 9 Cal.5th 279, 306 (Nationwide), quoting § 17500.)  The FAL is “‘designed to protect consumers from false or deceptive advertising.’”  (Id. at p. 305; see Kwikset Corp. v. Superior Court (2011) 51 Cal.4th 310, 331 [“The UCL and false advertising law are both intended to preserve fair competition and protect consumers from market distortions.”].)  “Like the choice of the term ‘unfair’ in the UCL, the governing substantive standard of the FAL—prohibiting advertising that is ‘untrue or misleading’ [citation]—is set forth in broad and open-ended language that is intended to permit a court of equity to reach any novel or creative scheme of false or misleading advertising that a deceptive business may devise.”  (Nationwide, supra, 9 Cal.5th at p. 308.)  “The FAL prohibits ‘“not only advertising which is false, but also advertising which, although true, is either actually misleading or which has a capacity, likelihood or tendency to deceive or confuse the public.”  [Citation.]  Thus, to state a claim under either the UCL or the false advertising law, based on false advertising or promotional practices, “it is necessary only to show that ‘members of the public are likely to be deceived.’”’ ”  (Ibid.)

 

 

(…) The remedies and penalties provided for in the UCL and FAL generally are cumulative to each other and to remedies and penalties available under other laws.  (§§ 17205, 17534.5.)  Thus, conduct that violates both the UCL and FAL can result in separate penalties of up to $2,500 for each UCL violation and for each FAL violation.  (See People v. Toomey (1984) 157 Cal.App.3d 1, 22 [the UCL and FAL “allow for cumulative remedies, indicating a legislative intent to allow ... double fines”]. (p. 21).

 

 

1

 

Target Audience Standard

i

 

“To prevail on a claim under the fraudulent prong of the Unfair Competition Law ‘based on false advertising or promotional practices,’ the plaintiff must ‘ “show that ‘members of the public are likely to be deceived.’ ” ’  [Citations.]  An advertisement or promotional practice is likely to deceive if it includes assertions that are (1) untrue, or (2) ‘ “true [, but are] either actually misleading or which [have the] capacity, likelihood or tendency to deceive or confuse the public.” ’ ”  (Shaeffer v. Califia Farms, LLC (2020) 44 Cal.App.5th 1125, 1135 (Shaeffer).)  The FAL “substantively overlaps” with the fraudulent prong of the UCL and the “burden under these provisions is the same:  To prevail on a claim under the false advertising law, the plaintiff must show that ‘ “ ‘members of the public are likely to be deceived ....’ ” ’ ”  (Id. at p. 1136; see also Chapman v. Skype Inc. (2013) 220 Cal.App.4th 217, 226 [for claims under “ ‘the UCL or the false advertising law, based on false advertising or promotional practices, “it is necessary only to show that ‘members of the public are likely to be deceived’ ” ’ ”] (Chapman).

 

 

In assessing the likelihood of deception, the challenged advertisement or practice is typically viewed “through the eyes of the ‘reasonable consumer’—that is, the ‘ordinary consumer acting reasonably under the circumstances....’ ”  (Shaeffer, supra,44 Cal.App.5th at p. 1135.)

 

 

However, “ ‘where the advertising or practice is targeted to a particular group or type of consumers, either more sophisticated or less sophisticated than the ordinary consumer, the question whether it is misleading to the public will be viewed from the vantage point of members of the targeted group, not others to whom it is not primarily directed.’ ”  (In re Vioxx Class Cases (2009) 180 Cal.App.4th 116, 130 (Vioxx), quoting Lavie v. Procter & Gamble Co. (2003) 105 Cal.App.4th 496, 509–510 (Lavie).)

 

 

A fraudulent or deceptive omission is actionable if it is “contrary to a representation actually made by the defendant, or an omission of a fact the defendant was obliged to disclose.”  (Daugherty v. American Honda Motor Co., Inc. (2006) 144 Cal.App.4th 824, 835; see Collins v. eMachines, Inc. (2011) 202 Cal.App.4th 249, 255 (Collins) [“fraud or deceit encompasses the suppression of a fact by one who is bound to disclose it, or the suppression of a fact that is contrary to a representation that was made”].)  In other words, omissions-based claims can be pure-omissions claims or partial-misrepresentation claims.

 

 

In assessing whether an omission is fraudulent or deceptive, courts typically consider whether the omission satisfies one or more of the four factors set forth in LiMandri v. Judkins (1997) 52 Cal.App.4th 326, 336.  As this court explained in LiMandri:  “There are ‘four circumstances in which nondisclosure or concealment may constitute actionable fraud:  (1) when the defendant is in a fiduciary relationship with the plaintiff; (2) when the defendant had exclusive knowledge of material facts not known to the plaintiff; (3) when the defendant actively conceals a material fact from the plaintiff; and (4) when the defendant makes partial representations but also suppresses some material facts.’ ” (LiMandri, at p. 336; see Collins, supra, 202 Cal.App.4th at p. 255 [applying the LiMandri factors to determine whether a failure to disclose constituted actionable fraud or deceit].

As previously noted, the governing standard in a false advertising case is whether “ ‘ “ ‘members of the public are likely to be deceived.’ ” ’ ”  (Nationwide, supra, 9 Cal.5th at p. 308.)  If the challenged advertisement is likely to deceive, it is actionable “without individualized proof of deception, reliance and injury.”  (Massachusetts Mutual Life Ins. Co. v. Superior Court (2002) 97 Cal.App.4th 1282, 1288; see Prata v. Superior Court (2001) 91 Cal.App.4th 1128, 1137 [“The Legislature considered [the UCL’s] purpose so important that it authorized courts to order restitution without individualized proof of deception, reliance and injury if necessary to prevent the use or employment of an unfair practice.”], italics omitted.)

 

 

(…) Similarly, in Hrymoc v. Ethicon, Inc. (N.J. Super. Ct. App. Div. 2021) 467 N.J. Super. 42 (Hrymoc), certification granted October 19, 2021, 085547, a patient suffered severe medical complications after receiving a Prolift implant.  She sued Ethicon under New Jersey’s products liability law and a jury returned a verdict in her favor on design defect and failure-to-warn theories of liability.  (Id. at pp. 199–200.)

 

 

(…) The Kaiser, Hrymoc, Hammons, and Carlino decisions arose in other jurisdictions and the plaintiffs’ claims in those cases were predicated on legal theories and trial records different than those presented here.  However, each decision reveals a similar narrative:  Ethicon disseminated IFUs that were likely to deceive doctors because the IFUs falsified or omitted the full range, severity, duration, and cause of complications associated with Ethicon’s pelvic mesh products, as well as the potential irreversibility and catastrophic consequences of those complications.  The statement of decision and the appellate record in the present case tell precisely the same story.  Viewing the evidence in the light most favorable to the People, as the prevailing party, we conclude there was substantial evidence to support the trial court’s factual finding that Ethicon’s IFUs were likely to deceive doctors.

 

 

Substantial Evidence Supported the Findings Regarding Ethicon’s Written Marketing Communications, But Not its Oral Marketing Communications

 

However, unlike the trial court, we conclude the uniform nature of Ethicon’s sales representatives training does not, standing alone, give rise to a reasonable inference that every single one of Ethicon’s thousands of oral communications with doctors included false or misleading statements.  The mere fact a sales representative may have been trained in a particular way—even in a manner that promoted the disclosure of misleading information—reveals little, if anything, about the content of any particular conversation that may have occurred many months or years later.  Further, there is no evidence—at least none of which we are aware of—suggesting Ethicon’s sales representatives read or recited a uniform script, Ethicon’s IFUs, or Ethicon’s printed marketing materials during their oral communications with doctors.

 

 

We hasten to add that there is nothing inherently less problematic about a false or deceptive statement that is spoken aloud, as opposed to one that has been memorialized in writing.  In an appropriate case, where the content and deceptive nature of the oral statement is established, the speaker may be held liable for violating the UCL or FAL.  (See People v. Dollar Rent-A-Car Systems, Inc. (1989) 211 Cal.App.3d 119, 128–129 [the FAL’s prohibition against false or misleading advertising “extends to the use of false or misleading oral statements”].)  We merely conclude there was insufficient evidence in this case regarding the substance of Ethicon’s oral marketing communications; thus, there was insufficient evidence that these communications were likely to deceive their target audiences.

 

 

Substantial Evidence Supported the Finding that Ethicon’s Marketing Was Likely to Deceive Patients.

 

 

Overview of the Safe Harbor Defense  

 

Under the safe harbor defense, “specific legislation may limit the judiciary’s power to declare conduct unfair under the UCL.  If the Legislature has permitted certain conduct or considered a situation and concluded no action should lie, courts may not override that determination. When specific legislation provides a ‘safe harbor,’ plaintiffs may not use the general unfair competition law to assault that harbor.”  (Cel-Tech, supra, 20 Cal.4th at p. 182.)  Stated another way, the Attorney General or another UCL plaintiff may “not ‘plead around’ an ‘absolute bar to relief’ simply ‘by recasting the cause of action as one for unfair competition.’ ”  (Ibid.)

 

 

The FDA Did Not Create a Safe Harbor for Communications Related to the POP Products

 

The FDA’s limited review of the draft Prolift and Prolift+M IFUs—a review undertaken as part of the section 510(k) clearance process—did not create a safe harbor.  “To forestall an action under the unfair competition law, another provision or executive action, per our stated assumptions must actually ‘bar’  the action or clearly permit the conduct.”  (Cel-Tech, supra, 20 Cal.4th at p. 183; Klein v. Chevron U.S.A., Inc. (2012) 202 Cal.App.4th 1342, 1379 [“to qualify for the ‘safe harbor’ rule, the defendant must show that a statute ‘explicitly prohibits liability for the defendant’s acts or omissions’ [citation] or ‘expressly precludes an action based on the conduct’ ”].)The FDA’s conduct during the clearance process did not clearly sanction or approve the final IFUs for non-510(k) purposes.  “ ‘The 510(k) process is focused on equivalence, not safety.’  ...  These determinations simply compare a post–1976 device to a pre–1976 device to ascertain whether the later device is no more dangerous and no less effective than the earlier device.’ ”  (Medtronic, Inc. v. Lohr (1996) 518 U.S. 470, 493; accord Kaiser, supra, 947 F.3d at p. 1018 [in products liability case, trial court properly excluded evidence that FDA cleared Prolift because the section 510(k) clearance process and FDA safety review serve different purposes].)

 

 

(…) The court found its calculation was likely an undercount because, for certain gaps of time, Ethicon did not have internal company data necessary for the Attorney General’s forensic accountant to calculate the number of deceptive IFUs and marketing communications that Ethicon disseminated.  These gaps of time were omitted from the violations count (fn. 16).

 

 

 

 

(California Court of Appeal, April 11, 2022, The People v. Johnson & Johnson, Docket No. D077945, Certified for Publication)

Friday, June 11, 2021

U.S. Court of Appeals for the Second Circuit, 1-800 Contacts, Inc. v. Federal Trade Commission, Docket No. 18-3848

Antitrust

 

Competition

 

Sherman Act and Unfair Competition

 

FTC

 

Section 5 of the FTC Act

 

Unfair Competition

 

Internet Advertisement

 

Search Advertising

 

Auctions Held by Companies That Operate Search Engines

 

Trademark Settlement Agreements

 

Does a Trademark Settlement Agreement Illegally Restrain Trade Under the Sherman Act?

 

Procompetitive Justification

 

Duress

 

Reverse Payment Patent Settlements

 

IP and Antitrust

 

 

 

1-800 Contacts, Inc., petitions from a Final Order of the Federal Trade Commission (FTC) finding that agreements between Petitioner 1-800 Contacts, Inc. and various competitors to, among other things, refrain from bidding on “keyword” search terms for internet advertisements, violate Section 5 of the FTC Act, 15 U.S.C. § 45.  We hold that although trademark settlement agreements are not immune from antitrust scrutiny, the FTC (1) improperly considered the agreements to be “inherently suspect” and (2) incorrectly concluded that the challenged agreements are a violation of the FTC Act under the “rule of reason”. »

 

PETITION FOR REVIEW GRANTED, FINAL ORDER VACATED AND REMANDED.

 

 

Between 2004 and 2013, Petitioner 1-800 Contacts, Inc. (“1-800”) entered into thirteen trademark settlement agreements and one sourcing and services agreement with competitors (the “Challenged Agreements”). As explained below, the Challenged Agreements contained provisions restricting specific terms on which the parties could “bid” when participating in auctions held by companies that operate search engines. By restricting bidding on terms in these auctions, the competitors agreed not to advertise their products when consumers used the search engines’ platforms to search the specific terms at issue.

 

 

Petitioner and its competitors pay to advertise their sales of contact lenses on the internet. One way they do this is via “search advertising”. ”When an online shopper uses a search engine such as Google or Bing, the search engine’s program returns two types of results to the shopper: “sponsored” and “organic,” both of which provide links to web pages.    Sponsored results are ads; they appear because the owner of the featured web page has paid for its page to appear in that space.      Sponsored links are typically designated by a label like “Ad” or “Sponsored,” and by colored or shaded boxes around the link. Organic results, on the other hand, appear based exclusively on which results a search engine’s algorithm deems to be most relevant to the shopper’s search. Organic results are listed separately from the sponsored results.

 

 

Search engines determine which advertisements to display on a search results page based in part on the relevance or relation of the consumer’s search to various words or phrases called “keywords.” Advertisers bid on these keywords during auctions hosted by the search engines. The highest bidders’ ads are typically displayed most prominently on a page, though search engines consider other factors when determining where to place an ad on a results page, such as an ad’s quality and relevance to a consumer’s search. Search engines generally do not limit the keywords available to advertisers at auction. As a result, competitors often bid on each other’s brand names so that their ad runs when a consumer searches for a competitor. Brand name terms are often trademarked.

 

 

Via bidding on “negative keywords,” an advertiser may also prevent its ad from being displayed when a consumer searches for a particular keyword. These negative keywords preclude ads from being displayed even when the search engine independently determined that the ad would be relevant to the consumer. The Commission suggests that this is useful when, for example, a retailer selling eyeglasses has bid on the advertising keyword “glasses” but wants to prevent its ad from appearing in response to the term “wine glasses.”

 

 

Because Petitioner charges more than other online retailers, when its competitors’ ads appear in response to a search for 1-800’s trademark terms, Petitioner’s sales tend to decrease.

 

 

3 Section 5 of the FTC Act states that “unfair methods of competition in or affecting commerce, and unfair or deceptive acts or practices in or affecting commerce, are hereby declared unlawful.” 15 U.S.C. § 45(a)(1).

 

 

In Actavis, the Supreme Court analyzed what are known as “reverse payment” patent settlements. 570 U.S. at 141. In short, manufacturers of brand name drugs paid manufacturers of generic drugs to keep the generic manufacturers from litigating the validity of the brand name manufacturers’ patents. See id. at 145. This effectively allowed the brand name manufacturers to maintain exclusive sales of certain drugs for longer than they would have if the applicable patent, through litigation, was found to be invalid. Id. at 153-54. In Actavis, the Court rejected the idea that the conduct at issue was immune from antitrust scrutiny just because it occurred within the context of a patent litigation settlement. Id. at 146-48. The Court explained that “it would be incongruous to determine antitrust legality by measuring the settlement’s anticompetitive effects solely against patent law policy, rather than by measuring them against procompetitive antitrust policies as well.” Id.at 148.

 

 

As in Actavis, Petitioner’s trademark, “if valid and infringed, might have permitted it to” preclude competitors from bidding on its trademarked terms in search advertising auctions or running advertisements on those terms. Id. at 147. We “take this fact as evidence that the agreement’s anticompetitive effects fall within the scope of” the trademark protections. Id. (internal quotation marks omitted). But the mere fact that an agreement implicates intellectual property rights does not “immunize an agreement from antitrust attack.” Id.; see also In re Indep. Serv. Orgs. Antitrust Litig., 203 F.3d 1322, 1325 (Fed. Cir. 2000) (“Intellectual property rights do not confer a privilege to violate the antitrust laws.”); United States v. Microsoft Corp., 253 F.3d 34, 63 (D.C. Cir. 2001) (same).  We have not shied away from considering antitrust claims that implicate trademark rights in the past, see, e.g.,Clorox Co. v. Sterling Winthrop, Inc., 117 F.3d 50, 55-56 (2d Cir. 1997), and we decline to do so now. As in any antitrust case, we must “determine whether the restraints in the agreements are reasonable in light of their actual effects on the market and their pro-competitive justifications.” Id. at 56.

 

 

I.              Sherman Act Framework

 

Because “the FTC Act's prohibition of unfair competition and deceptive acts or practices. . .  overlaps the scope of § 1 of the Sherman Act. . . aimed at prohibiting restraint of trade,” California Dental Ass'n v. FTC (Cal. Dental), 526 U.S. 756, 762 n. 3 (1999), it was appropriate that the ALJ and the Commission consulted Sherman Act jurisprudence to determine whether the Challenged Agreements violated Section 5 of the FTC Act. See Realcomp II, Ltd. v. FTC, 635 F.3d 815, 824 (6th Cir. 2011); North Carolina Bd. of Dental Examiners v. FTC, 717 F.3d 359, 370-71 (4th Cir. 2013) (recognizing a Section 1 violation as a “species” of unfair competition prohibited under the FTC Act).

 

 

To prove a Sherman Act violation – and by extension, a Section 5 violation – the FTC must establish (1) a contract, combination, or conspiracy exists that (2) unreasonably restrains trade. See Major League Baseball Props., Inc. v. Salvino, Inc. (MLB), 542 F.3d 290, 315-16 (2d Cir. 2008). In this case, the Challenged Agreements are undeniably contracts between Petitioner and its competitors. We “presumptively apply” what is known as the “rule of reason” analysis to the Challenged Agreements to determine whether they restrain trade. Texaco Inc. v. Dagher, 547 U.S. 1, 5 (2006). Under that analysis an antitrust plaintiff “must demonstrate that a particular contract or combination is in fact unreasonable and anticompetitive before it will be found unlawful.” Id. As Justice Brandeis famously articulated:

 

 

The true test of legality is whether the restraint imposed is such as merely regulates and perhaps thereby promotes competition or whether it is such as may suppress or even destroy competition. To determine that question the court must ordinarily consider the facts peculiar to the business to which the restraint is applied; its condition before and after the restraint was imposed; the nature of the restraint and its effect, actual or probable. The history of the restraint, the evil believed to exist, the reason for adopting the particular remedy, the purpose or end sought to be attained, are all relevant facts. This is not because a good intention will save an otherwise objectionable regulation or the reverse; but because knowledge of intent may help the court to interpret facts and to predict consequences. Chicago Board of Trade v. United States, 246 U.S. 231, 238 (1918).

 

 

The Supreme Court, however, has rejected fixed categories of analysis when considering the anticompetitive nature of a restraint. See Cal. Dental, 526 U.S. at 779. Some restraints, therefore, fall between the type of conduct typically labeled per se anticompetitive and that which is analyzed under a “full-blown” rule of reason analysis. MLB, 542 F.3d at 317. When “the great likelihood of anticompetitive effects can easily be ascertained,” courts apply an abbreviated rule of reason analysis sometimes known as the “quick-look” approach. Cal. Dental, 526 U.S. at 770. The Commission calls the standard it applies in these situations the “inherently suspect” framework. 5 JA 291. Under the Commission’s “inherently suspect” framework, neither direct evidence of harm nor proof of market power is needed to show the anticompetitive effect of the restraint because the “likely tendency to suppress competition” posed by the challenged conduct makes it “inherently suspect. ”Polygram Holding, Inc., 136 F.T.C. 310, 344-45 (2003), aff’d, 416 F.3d 29 (D.C. Cir. 2005). An “elaborate market analysis” is unnecessary, Polygram, 416 F.3d at 35, and once the government has identified a “suspect” agreement, the burden shifts directly to the defendant to show any procompetitive justifications it might have for the restraint. See United States v. Apple, 791 F.3d 290, 330 (2d Cir. 2015).

 

 

 

(…) But even if restraints on truthful advertising have a tendency to raise prices, “the fact that a practice may have a tangential relationship to the price of the commodity in question does not mean that a court should dispense with a full rule-of-reason analysis.” MLB, 542 F.3d at 317.

 

 

Crucially, the restraints at issue here could plausibly be thought to have a net procompetitive effect because they are derived from trademark settlement agreements. In Clorox, applying the rule of reason, we considered whether a trademark settlement agreement illegally restrained trade under the Sherman Act and we explained that “trademarks are by their nature non-exclusionary.” 117 F.3d at 55-56. Agreements to protect trademarks, then, should not immediately be assumed to be anticompetitive – in fact, Clorox tells us instead to presume they are procompetitive. Id. at 60. As the Challenged Agreements restrict the parties from running advertisements on Petitioner’s trademarked terms, they directly implicate trademark policy.

 

 

The Commission acknowledged as much, finding Petitioner’s proffered procompetitive justifications to be “cognizable and, at least, facially plausible.” JA 296. Rather than take that fact as an indication that it should not apply an abbreviated rule of reason analysis, as the Supreme Court instructed in California Dental, the Commission instead set out to show (i) that there was a theoretical basis for the alleged anticompetitive effect and that the restraints were likely, in this particular context, to harm competition and (ii) that Petitioner could have minimized the anticompetitive effects and accomplished its procompetitive justifications through less restrictive means. While this may be analytically acceptable in some situations, see Cal. Dental, 526 U.S. at 779 (noting to require a “more extended examination” does not always translate to a call for “plenary market examination”), it was not appropriate here.

 

 

Courts do not have sufficient experience with this type of conduct to permit the abbreviated analysis of the Challenged Agreements undertaken by the Commission. See Cal. Dental, 526 U.S. at 781 (explaining that the quick-look approach may be applicable if rule-of-reason analyses in case after case reach identical conclusions); Polygram, 416 F.3d at 36-37 (accepting the Commission’s definition of “inherently suspect” as describing restraints previously condemned by both “judicial experience and economic learning”). While both California Dental and Polygram consider advertising restraints, there are key differences between the restraints in those cases and the restraints here, and our own precedent suggests that trademark agreements like those at issue here need to be examined using a fuller analysis. See Clorox, 117 F.3d at 55-56, 59 (applying a rule of reason analysis and rejecting the alleged anticompetitive harm of a trademark agreement); see also Actavis, 570 U.S. at 158-59 (rejecting the application of a quick-look analysis for intellectual property agreements).

 

 

When, as here, not only are there cognizable procompetitive justifications but also the type of restraint has not been widely condemned in our “judicial experience,” see Polygram, 416 F.3d at 37, more is required. Cf. Bogan v. Hodgkins, 166 F.3d 509, 514 n.6 (2d Cir. 1999) (noting pre-California Dental that “under quick look, once the defendant has shown a procompetitive justification for the conduct, the court must proceed to weigh the overall reasonableness of the restraint using a full-scale rule of reason analysis” (internal quotation marks and citation omitted)). The Challenged Agreements, therefore, are not so obviously anticompetitive to consumers that someone with only a basic understanding of economics would immediately recognize them to be so. 7 See Cal. Dental, 526 U.S. at 770. We are bound, then, to apply the rule of reason.

 

 

III. Application of the Rule of Reason

 

Under the rule of reason, the Commission bears the burden of establishing a prima facie case of anticompetitive effect. Direct evidence of anticompetitive effects establishes a prima facie case of a Sherman Act Section 1 violation and obviates the need for a detailed market analysis or showing of market power.

 

 

(We also reject the Commission and amici’s arguments that the restrictions constitute illegal bid rigging as support for their use of the inherently suspect framework. An absolute ban on competitive bidding, or bid rigging, would be anticompetitive on its face and may justify an abbreviated rule of reason analysis. Cal. Dental, 570 U.S. at 770 (citing Nat'l Soc'y of Prof'l Eng'rs v. FTC, 435 U.S. 679, 692-93 (1978)); see also United States v. Joyce, 895 F.3d 673, 679 (9th Cir. 2018) (finding bid rigging to be per se illegal). It is not clear to us, however, that the restrictions constitute such a ban. The Challenged Agreements do not prevent the parties from participating in keyword auctions, only from bidding on trademarked terms. Whether restrictions on advertisers’ use of particular terms leads to overall harm to the search engines is not obvious and therefore does not justify analyzing the agreements under the inherently suspect framework. Nor, as amici in support of the government argue, is it obvious that the restrictions constitute market division, another type of restraint that would justify an abbreviated analysis. See Palmer v. BRG of Georgia, Inc., 498 U.S. 46 (1990) (per curiam (fn. 8)).

 

 

 

A.   Anticompetitive Effect

 

Anticompetitive effects in a relevant market may be shown through direct evidence of output reductions, increased prices, or reduced quality in the relevant market. Ohio v. Am Express Co. (Am. Express), 138 S. Ct. 2274, 2284 (2018); see also North Am. Soccer League, 883 F.3d at 42. The Commission has also defined sufficient evidence of anticompetitive harm to include evidence of “retarded innovation, or other manifestations of harm to consumer welfare.” In re Realcomp II Ltd., No. 9320, 2007 WL 6936319 (F.T.C. Oct. 30, 2009), aff’d 635 F.3d 815. We reject the Commission’s argument that it has established direct evidence of anticompetitive effect in the form of increased prices. When an antitrust plaintiff advances an antitrust claim based on direct evidence in the form of increased prices, the question is whether it can show an actual anticompetitive change in prices after the restraint was implemented. See Brooke Grp. Ltd. v. Brown & Williamson Tobacco Corp., 509 U.S. 209, 236-37 (1993); MacDermid, 833 F.3d at 184. The government could not make that showing because it did not conduct an empirical analysis of the Challenged Agreements’ effect on the price of contact lenses in the online market for contacts. The evidence offered by the government is theoretical and anecdotal; 10 it is not “direct.” Consequently, the Commission’s conclusion that differences between 1-800 Contacts’ prices and those of its competitors constitute direct evidence of the Challenged Agreements’ anticompetitive effects is not supported by substantial evidence.

 

 

10 The government argues, inter alia, that (a) Petitioner admits that it charges more than their competitors in the relevant market; (b) economic theory strongly suggests that advertising restrictions tend to increase prices of any given product; and (c) Petitioner offered to meet or beat any price offered by other online retailers. Even accepting all this as true, it is not direct evidence that the Challenged Agreements caused the price of contact lenses in the relevant market to rise, as our precedent requires. MacDermid, 833 F.3d at 184.

 

 

11 A slightly different issue plagues the government’s argument that there is direct evidence of reduced revenues for search engines. To show this, the government did not show that Google or Microsoft, the companies who control the two most popular search engines, had lower revenues after the Challenged Agreements were put into place. Nor did the government introduce evidence that Petitioner spent less money on search advertising than it did before the Challenged Agreements came into effect. Instead, the government offered empirical evidence that the Challenged Agreements reduced the price paid by Petitioner for each click on one of its keywords. JA 1096-99. Empirical evidence is, as noted, required under our caselaw to find direct evidence of an anticompetitive effect. K.M.B., 61 F.3d at 127. But showing that a price for certain keywords dropped is not direct evidence of the effect on the market as a whole. See Clorox, 117 F.3d at 56 (quoting K.M.B., 61 F.3d at 127). This snapshot shows only that Petitioner paid less for certain keyword advertisements, no more and no less.

 

 

(…) Blackburn v. Sweeney, 53 F.3d 825, 827-29 (7th Cir. 1995) (identifying an agreement not to advertise in certain geographic areas as a per se illegal attempt to allocate markets)

 

 

(…) We need not decide whether the Commission’s theory of harm is viable, however, because we conclude that Petitioner has shown a procompetitive justification and the Commission fails to carry its burden at the third step.

 

 

B.   Procompetitive Justifications

 

 

Petitioner asserts that the Challenged Agreements are justified by two procompetitive effects: reduced litigation costs and protecting Petitioner’s   trademark rights. The Commission found that, while both of these justifications were “cognizable and facially plausible,” Petitioner did not show that they “have a basis in fact,” and therefore they were not “valid.”   JA 309. We disagree. The protection of Petitioner’s trademark interests constitutes a valid procompetitive justification for the Challenged Agreements. The Commission determined that, since “the Challenged Agreements restrict a type of competitive advertising that has never been found to violate the trademark laws, and the weight of authority overwhelmingly points to non-infringement,” trademark protection was not a valid procompetitive benefit that justified the Challenged Agreements. JA 313. This was incorrect. Trademarks are by their nature non-exclusionary, and agreements to protect trademark interests are “common, and favored, under the law.” Clorox, 117 F.3d at 55. As a result, “it is difficult to show that an unfavorable trademark agreement creates antitrust concerns.” Id.at 57. This is true even though trademark agreements inherently prevent competitors “from competing as effectively as they otherwise might.” Id.at 59.

 

 

In Clorox, we found that the plaintiff had failed to show adverse effects on the market as a whole because the restrictions at issue did not restrict competitors’ ability to enter into the relevant market. Id. at 59. Although we held that the plaintiff in that case failed to present a prima facie case of anticompetitive harm, we also went on to detail how the procompetitive justifications of the agreement weighed against finding an antitrust violation. Id. at 60. We stated that “trademark agreements are favored in the law as a means by which parties agree to market products in a way that reduces the likelihood of consumer confusion and avoids time-consuming litigation.” Id. And again, Clorox counsels that we should “presume” that trademark settlement agreements are procompetitive. Id 14. It has not been argued that exceptional circumstances exist in this case. We, therefore, need not decide what circumstances might qualify as exceptional, von Hofe v. United States, 492 F.3d 175, 185 n.3 (2d Cir. 2007), such as, for example, agreements between parties with unequal bargaining power. See Clorox, 117 F.3d at 60 (“There is no evidence that a party to the challenged agreement entered the agreement under duress.”).

 

 

 

C.  Less Restrictive Alternatives

 

Because Petitioner has carried its burden of identifying a procompetitive justification, the government must show that a less restrictive alternative exists that achieves the same legitimate competitive benefits. 16 Am. Express, 138 S. Ct. at 2284; North Am. Soccer League, 883 F.3d at 42. That is, the restraint “only survives a rule of reason analysis if it is reasonably necessary to achieve the legitimate objectives proffered by the defendant.” United States v. Brown Univ., 5 F.3d 658, 678-79 (3d Cir. 1993). “Less restrictive alternatives are those that would be less prejudicial to competition as a whole. ”North Am. Soccer League, 883 F.3d at 45 (internal quotation marks omitted). The Commission found that the government had shown a viable less restrictive alternative, namely that the parties to the Challenged Agreements could have agreed to require clear disclosure in each search advertisement of the identity of the rival seller rather than prohibit all advertising on trademarked terms. According to the government, therefore, the Challenged Agreements are overbroad. In Clorox, however, we noted that “it is usually unwise for courts to second-guess” trademark agreements between competitors. 117 F.3d at 60. In this context, what is “reasonably necessary,” Brown Univ., 5 F.3d at 679, is likely to be determined by competitors during settlement negotiations, Clorox, 117 F.3d at 60. And, as articulated above, absent something that would negate the typically procompetitive nature of these agreements, “the parties’ determination of the scope of needed trademark protections is entitled to substantial weight.” Clorox, 117 F.3d at 60.

 

 

(…) When the restraint at issue in an antitrust action implicates IP rights, Actavis directs us to consider the policy goals of the relevant IP law.   See 570 U.S. at 149. Here, those considerations must include the practical implications of the government’s proffered alternatives on the parties’ ability to protect and enforce their trademarks.

 

 

 

CONCLUSION

 

In this case, where the restrictions that arise are born of typical trademark settlement agreements, we cannot overlook the Challenged agreements’ procompetitive goal of promoting trademark policy. In light of the strong procompetitive justification of protecting Petitioner’s trademarks, we conclude the Challenged Agreements “merely regulate and perhaps thereby promote competition.” Chicago Bd. of Trade, 246 U.S. at 238. They do not constitute a violation of the Sherman Act, and therefore an asserted violation of the FTC Act fails of necessity. The petition for review is GRANTED, the Final Order of the Federal Trade Commission is VACATED, and the case is REMANDED with instructions to DISMISS the administrative complaint.

 

 

17 We acknowledge a concern that the Challenged Agreements require the parties to employ negative keywords, which prevent ads of competitors from appearing in a consumer search for each other’s trademarked terms – even absent purchase of a keyword (but rather due to a search engine’s independent determination that an ad is relevant to the consumer). Even if we were inclined to consider whether this aspect of the settlement agreement goes beyond any legitimate claim of trademark infringement, and therefore imposes a restraint on competition not justified by the procompetitive value of enforcing trademark rights, the Commission has neither made separate findings with respect to the specific anticompetitive effects of this narrow aspect of the settlement agreements, nor urged that we should evaluate this issue separately. Accordingly, we have no reason to consider that issue.

 

 

 

 

 

 

Secondary authority: Phillip E. Areeda & Herbert Hovenkamp, Antitrust Law: An Analysis of Antitrust Principles and Their Application ¶ 1502 (3rd & 4th eds., 2019 Cum. Supp. 2010-2018)

 

 

 

 

(U.S. Court of Appeals for the Second Circuit, June 11, 2021, 1-800 Contacts, Inc. v. Federal Trade Commission, Docket No. 18-3848)